Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free CNXU Stock Alerts

Conexeu Sciences (CNXU) Competitors

Conexeu Sciences logo
$5.70 -0.17 (-2.81%)
As of 02:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CNXU vs. SSII, ANGO, KIDS, BWAY, and DCTH

Should you buy Conexeu Sciences stock or one of its competitors? Conexeu Sciences's main competitors and comparable companies include SS Innovations International (SSII), AngioDynamics (ANGO), OrthoPediatrics (KIDS), Brainsway (BWAY), and Delcath Systems (DCTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Conexeu Sciences compare to SS Innovations International?

Conexeu Sciences (NASDAQ:CNXU) and SS Innovations International (NASDAQ:SSII) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Conexeu Sciences has a net margin of 0.00% compared to SS Innovations International's net margin of -23.73%. Conexeu Sciences' return on equity of 0.00% beat SS Innovations International's return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
SS Innovations International -23.73%-26.77%-15.01%

Conexeu Sciences currently has a consensus target price of $20.00, suggesting a potential upside of 255.11%. SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 108.96%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than SS Innovations International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
SS Innovations International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Conexeu Sciences has higher earnings, but lower revenue than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Conexeu Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
SS Innovations International$52.40M12.81-$12.13M-$0.06N/A

In the previous week, SS Innovations International had 1 more articles in the media than Conexeu Sciences. MarketBeat recorded 3 mentions for SS Innovations International and 2 mentions for Conexeu Sciences. SS Innovations International's average media sentiment score of 1.18 beat Conexeu Sciences' score of 1.16 indicating that SS Innovations International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SS Innovations International
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Conexeu Sciences beats SS Innovations International on 8 of the 12 factors compared between the two stocks.

How does Conexeu Sciences compare to AngioDynamics?

Conexeu Sciences (NASDAQ:CNXU) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

89.4% of AngioDynamics shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Conexeu Sciences has a net margin of 0.00% compared to AngioDynamics' net margin of -11.48%. Conexeu Sciences' return on equity of 0.00% beat AngioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
AngioDynamics -11.48%-5.73%-3.77%

Conexeu Sciences has higher earnings, but lower revenue than AngioDynamics. Conexeu Sciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
AngioDynamics$320.17M2.04-$36.74M-$0.87N/A

Conexeu Sciences currently has a consensus price target of $20.00, indicating a potential upside of 255.11%. AngioDynamics has a consensus price target of $19.50, indicating a potential upside of 23.57%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than AngioDynamics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
AngioDynamics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40

In the previous week, AngioDynamics had 3 more articles in the media than Conexeu Sciences. MarketBeat recorded 5 mentions for AngioDynamics and 2 mentions for Conexeu Sciences. AngioDynamics' average media sentiment score of 1.16 beat Conexeu Sciences' score of 1.16 indicating that AngioDynamics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AngioDynamics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AngioDynamics beats Conexeu Sciences on 9 of the 15 factors compared between the two stocks.

How does Conexeu Sciences compare to OrthoPediatrics?

Conexeu Sciences (NASDAQ:CNXU) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Conexeu Sciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -15.72%. Conexeu Sciences' return on equity of 0.00% beat OrthoPediatrics' return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
OrthoPediatrics -15.72%-8.10%-5.54%

69.1% of OrthoPediatrics shares are owned by institutional investors. 32.5% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Conexeu Sciences presently has a consensus target price of $20.00, indicating a potential upside of 255.11%. OrthoPediatrics has a consensus target price of $26.44, indicating a potential upside of 14.70%. Given Conexeu Sciences' higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than OrthoPediatrics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

In the previous week, OrthoPediatrics had 35 more articles in the media than Conexeu Sciences. MarketBeat recorded 37 mentions for OrthoPediatrics and 2 mentions for Conexeu Sciences. Conexeu Sciences' average media sentiment score of 1.16 beat OrthoPediatrics' score of 0.53 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OrthoPediatrics
21 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Conexeu Sciences has higher earnings, but lower revenue than OrthoPediatrics. Conexeu Sciences is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
OrthoPediatrics$252.72M2.38-$39.65M-$1.68N/A

Summary

Conexeu Sciences and OrthoPediatrics tied by winning 7 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Brainsway presently has a consensus price target of $18.20, indicating a potential upside of 27.18%. Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 255.11%. Given Conexeu Sciences' higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainsway
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Brainsway has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainsway$60.70M9.48$7.57M$0.4432.52
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A

Brainsway has a net margin of 15.65% compared to Conexeu Sciences' net margin of 0.00%. Brainsway's return on equity of 12.74% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Brainsway15.65% 12.74% 8.17%
Conexeu Sciences N/A N/A N/A

30.1% of Brainsway shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Brainsway had 10 more articles in the media than Conexeu Sciences. MarketBeat recorded 12 mentions for Brainsway and 2 mentions for Conexeu Sciences. Conexeu Sciences' average media sentiment score of 1.16 beat Brainsway's score of 0.79 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Brainsway
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Brainsway beats Conexeu Sciences on 12 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Delcath Systems?

Conexeu Sciences (NASDAQ:CNXU) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Conexeu Sciences had 1 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for Conexeu Sciences and 1 mentions for Delcath Systems. Conexeu Sciences' average media sentiment score of 1.16 beat Delcath Systems' score of 0.98 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Delcath Systems
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Conexeu Sciences currently has a consensus target price of $20.00, indicating a potential upside of 255.11%. Delcath Systems has a consensus target price of $23.17, indicating a potential upside of 40.83%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Delcath Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Delcath Systems has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
Delcath Systems$95.42M5.98$2.70M$0.011,645.00

Delcath Systems has a net margin of 0.56% compared to Conexeu Sciences' net margin of 0.00%. Delcath Systems' return on equity of 0.46% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
Delcath Systems 0.56%0.46%0.42%

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Delcath Systems beats Conexeu Sciences on 12 of the 15 factors compared between the two stocks.

Get Conexeu Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNXU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNXU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNXU vs. The Competition

Export
MetricConexeu SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$151.33M$5.71B$7.21B$12.70B
Dividend YieldN/A1.75%2.54%11.69%
P/E Ratio-51.4125.85273.1925.00
Price / SalesN/A70.51601.6377.76
Price / CashN/A33.1677.2052.85
Price / BookN/A6.1012.796.08
Net Income-$3.92M$147.75M$3.47B$348.75M
7 Day Performance-19.20%-1.00%-0.32%-1.72%
1 Month Performance-32.23%6.25%7.86%3.51%
1 Year PerformanceN/A6.29%24.53%14.72%

Conexeu Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNXU
Conexeu Sciences
3.7763 of 5 stars		$5.71
-2.8%		$20.00
+250.6%		N/A$152.69MN/AN/A4
SSII
SS Innovations International
2.531 of 5 stars		$3.48
+1.8%		$7.00
+101.1%		-52.3%$685.32M$42.49MN/A4
ANGO
AngioDynamics
3.172 of 5 stars		$15.85
+0.4%		$19.50
+23.0%		+54.6%$652.22M$320.17MN/A760
KIDS
OrthoPediatrics
2.9088 of 5 stars		$23.65
+1.4%		$26.44
+11.8%		+7.7%$608.88M$236.35MN/A200
BWAY
Brainsway
4.5094 of 5 stars		$14.30
-0.7%		$16.95
+18.5%		+83.4%$577.89M$52.22M32.50120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CNXU) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...
Stansberry Research | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel